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Summary: In 49 patients with benign prostatic hyperplasia, 24 metastatic prostatic carcinoma patients all under
palliative hormonal treatment, 17 untreated prostatic carcinoma patients without metastases and 14 untreated pros-
tatic carcinoma patients with metastases, plasma levels of thrombin-antithrombin III complex, D-dimer and plasmin-
a2-antiplasmin were determined.
The coagulation activation marker thrombin-antithrombin III complex did not show any significant difference
between the different patient groups. Of the fibrinolysis markers, D-dimer levels were elevated in both metastatic
groups compared to the non-metastatic group and the benign prostatic hyperplasia group. Surprisingly, the levels
of the other fibrinolysis marker, plasmin-a2-antiplasmin, showed no significant difference. The nature of these
findings is discussed and related to other relevant literature. The general conclusion is that fibrinolysis may not
play such a prominent role in prostatic carcinoma as described and expected.
Introduction
Prostatic carcinoma can affect the coagulation and fibri-
nolytic system (1, 2). The first report on coagulation
abnormalities in a patient with a prostatic carcinoma was
published more than 60 years ago (3). In the last de-
cades, attention was drawn to coagulation and fibrinoly-
sis abnormalities in patients with prostatic carcinoma
treated with estrogens. Estrogen treatment in patients
with prostatic carcinoma is associated with a significant
decrease in antithrombin III (4). Coagulation and fibri-
nolysis abnormalities in non-treated patients or non-
estrogen treated patients with prostatic carcinoma, have
not been addressed frequently. In the present study, co-
agulation and fibrinolysis activation (fig. 1) was deter-
mined in patients with prostatic carcinoma, non-estrogen
hormonally treated or non-treated, and in patients with
benign prostate hypertrophy. Coagulation activation was
assessed by the thrombin-antithrombin III complex, a
sensitive marker which indicates generation of thrombin
in vivo (5). The fibrinolytic system activity was eval-
uated by measuring the D-dimer and the plasmin-a2-
antiplasmin. D-dimer is produced as a result of cleavage
of cross-linked fibrin by plasmin. D-dimer reflects in
vivo plasmin-induced fibrinolysis (6). Plasmin-a2-anti-
plasmin is a relatively new assay and a sensitive marker
for plasmin generation in vivo (5). In the last few years
some studies were published in which plasmin-a2-anti-
plasmin was determined in patients with different kinds
of solid tumours, arterial thromboembolism and dissem-
inated intravascular coagulation with a variety of un-
derlying diseases (5—8). To our knowledge, plasmin-a2-
antiplasmin was never measured before in a group of
patients with prostatic carcinoma.
Materials and Methods
Patients
All patients visited the urological outpatient department. In every
prostatic carcinoma patient, the diagnosis was proven after histo-
logical examination of prostatic tissue. This tissue was obtained by
means of prostatic biopsy. These patients underwent an abdominal
CT-scan, a bone scan and a chest X-ray for further staging. In some
patients the prostatic carcinoma was discovered after a transure-
thral prostate resection for benign prostatic hyperplasia. The histo-
logical examination of the resected prostate chips, however,
showed a small adenocarcinoma. These patients underwent the
same investigations for further staging.
The diagnosis of benign prostate hypertrophy was made when the
patient presented with complaints of prostatism, when rectal ex-
amination revealed a benign prostate and a flowmetry showed a
maximum flow rate of less than 10 ml/s.
Patients taking anticoagulant drugs and patients with a history of
bleeding or thrombo-embolic disease were excluded.
The patients with benign prostate hypertrophy formed a group of
49 patients (group 1). The 55 patients with prostatic carcinoma
were divided into 3 groups. Group 2 consisted of 24 patients who
had lymphatic and/or haematologic metastases and who were being
hormonally treated at the time of blood sample taking. Twelve pa-
tients received gonadoreline analogues, nine patients anti-andro-
gens and three patients estramustine phosphate. The median dura-
tion of the hormonal therapy was 25 months (25—75th percentile:
8—43 months). Group 3 consisted of 17 patients without lymphatic
and/or haematologic metastases who had not received any kind of
treatment at the time of blood sample taking. Patients with lym-
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Fig. 1 Relevant part of the coagulation and fibrinolysis cascade.
phatic and/or haematologic metastases who had not received any
kind of treatment at the time of blood sample taking formed group
4(14 patients). In all patients, the haematological metastases were
bone metastases.
Samples and methods
Blood samples were drawn from a cubital vein in sitting position
before any prostatic manipulation took place. The various constitu-
ents were determined in citrated plasma. This was prepared by cen-
trifugation of a mixture of nine volumes freshly drawn blood with
one volume trisodium citrate (0.11 mol/1) during 30 minutes
(1600 g) at 25 °C. The plasma was stored at -70 °C in plastic
tubes and thawed at 37 °C for 5 minutes before batch analysis.
For the thrombin-antithrombin III complex determination, an Elisa
test kit was used (Behring Corporation, Marburg, Germany) (intra-
assay CV = 7.1%). The fibrin degradation products were measured
by means of the D-dimer test of the Behring Corporation (Marburg,
Germany) (intra-assay CV = 4.9%).
For the plasmin-a2-antiplasmin measurements, the Elisa test kit En-
zygnost® plasmin-a2-antiplasmin of the Behring Corporation (Mar-
burg, Germany) was employed (intra-assay CV = 5.4%). As a ref-
erence point, additionally, prostate-specific antigen was determined
in serum by the method of Pharmacia Delfia PSA (Rubi Pharmacia,
Woerden, The Netherlands).
Statistics
The Mann-Whitney-Wilcoxon test for paired samples and the χ2-
test, where appropriate, were used. A p-value less than 0.05 was
considered to be statistically significant.
Results
The median values and p-values are listed in table 1 and
the proportions of decreased or increased values and p-
values are listed in table 2.
No significant difference in thrombin-antithrombin II
complex values was found between the different groups.
A trend toward significance though, was found between
the untreated group with metastases and the benign pros-
tate hypertrophy group. Thrombin-antithrombin III com-
plex was higher in the untreated cancer group with me-
tastases compared to the benign prostate hypertrophy
group and the p-value was nearly significant (0.08). A
significantly larger proportion of both metastatic groups
had increased thrombin-antithrombin III complex and
D-dimer values compared to the benign prostate hyper-
trophy group and the non-metastatic group.
The D-dimer levels showed significant differences be-
tween the benign prostate hypertrophy group and the
treated group with metastases (p < 0.05), between the
treated group with metastases and the untreated group
without metastases (p < 0.01) and between both un-
treated groups (p < 0.05). In all cases, D-dimer levels
were significantly higher in the metastatic cancer
Geenen et al.: Coagulation and fibrinolysis activation markers in prostate cancer 71
ο^
I
ο
OJI
'S
I
'·&
£
Ό
i
Iυ
'S"1
u
0,
•c
in
7
th
es
1/3
1
11
I-H
•s
1
"M
a
8gu
s_
v*
g
'> ™
a) S o
C κι S?o ja ω
'111
ο
•S
"S w
^ *> *n
a SSS g S
Ι έ §
•5
^ ω
2 S_Ή *3 Ό§ a
• t? ee08 g 0cu ε
fH J
S w >»
« .!> 1
ce υ P»?
P« JD J3
H
O
O
δ
(NO
cn
O
M
<N
O
*
>
o
m
O
05
j^0
85
o
1s
^" ς. ΙΛ> '*3
1*1 7 |
olEI.
/—s
«^
 c m S&|7 §8 T? «ή βS^S,
^
ωΜ
 c <n S
o« S r- cf ··! ι g
δ ! 5 E o,
/—s1»
Ja
ϊ-17'l
olEl
<n Ο
0 0
ο ο
V V
ο
V
ο
0
V
oo «n oo ®ο ο ο ο
ο ο V
ο
0
V
—Ρ ON °.0 0 0
V ο V
»η
Ρ ο ο S
.· ηη r-r\ ^>
Τ «^ Ι _ Ι1
 Ι ο ° r-
.« «η Λ ο ^ νο ,νί
•(Ν f^ ^ °CNJ "nie
^, S* ΓΙON /-*\ Ο *
• ο ^Q ι"7
" Τ i ^Τt^ oo ji. ο Ξ ^ σ>
~ ^(^ ο ® §g
^ «η oo 22
^ 7 1 Το Λ ο !5 ^ ο
S mCi ooG ?*a fNCi
^^ o" o"
2 S? 3 27 °° ^ ^
ON · ^H ^5 fsj ^^ rsj · r\l
^ Γ^ N—^ *O N^X ^ sj/ ^ sjx
^^I
X.
*p,
CJ ^N ™^Ξ 3 3
i Ϊ 1C "^ *
o .2 »
£ .& o1 ^ 1 s§ l ! g.
C N-' ψ
0 ^ 2 ω Ε υ
-D S E P S
^5 o 'S c
groups. A borderline significant difference was found
between the benign prostate hypertrophy group and the
untreated group with metastases (p = 0.05).
No significant difference was found between the median
plasmin-a2-antiplasmin levels of the different groups.
Plasmin-a2-antiplasmin was higher in both metastatic
groups compared to the benign prostate hypertrophy
group and the p-value was nearly significant, 0.09 for
benign prostate hypertrophy versus treated metastatic
group and 0.08 for benign prostate hypertrophy versus
untreated metastatic group. The metastatic cancer group
without treatment had significantly more patients with
increased plasmin-a2-antiplasmin levels compared to all
three other groups.
Discussion
It has been reported that fibrinolysis seems to play a
prominent role in (metastatic) prostatic carcinoma, as
indicated by increased D-dimer levels and increased
urokinase-type plasminogen activator levels in the blood
of patients with (metastatic) prostatic carcinoma (1, 2,
9, 10). In our patient groups, increased D-dimer levels
were found in the treated cancer group with metastases.
Between the two untreated cancer groups, the D-dimer
levels were higher in the group with metastases com-
pared to those in the group without metastases.
Surprisingly, the plasmin-a2-antiplasmin levels did not
show an increase. This might be a methodological prob-
lem as a result of the action of neutrophil elastase, which
is enhanced in carcinoma patients. Elastase can degrade
fibrin so that similar, but not identical, fibrin split pro-
ducts are formed and the trigger for reactive plasmin-
a2-antiplasmin formation is not really strong. On the
other hand it has been reported that D-dimer test kits
detect both plasmin- and neutrophil elastase-derived
split products (11). So, there are two pathways, which
supply substances reacting in the D-dimer test and only
one pathway in which plasmin-a2-antiplasmin formation
is provoked. This might explain why significantly
increased median D-dimer values have been found and
were found in the present study in patients with prostatic
carcinoma and no significant increase in median plas-
min-a2-antiplasmin values was found in prostatic carci-
noma patients in the present study.
To our knowledge, there has been only one study pub-
lished in which thrombin-antithrombin III complex was
measured in patients with prostatic carcinoma (1).
Thrombin-antithrombin III complex was higher in the
prostatic cancer group compared to two control groups,
but no p-value was mentioned. The cancer group con-
sisted of 5 1 patients with different stages of prostatic
carcinoma. One control group consisted of 40 blood do-
Z H Q &, OH nors and the other of 20 patients with benign prostate
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Tab. 2 Proportions of decreased (D) or increased (I) values (%) in the various patients groups.
Analytes
Thrombin-antithrombin III
(Reference values) Patients with
benign prostate
hypertrophy
Group 1
D I
(1.04-4.1 ug/1) 0 12.2
Patients with
metastases,
treated
Group 2
D I
0 29.2
Patients with-
out metastases,
untreated
Group 3
D I
0 5.9
Patients with
metastases,
untreated
Group 4
D I
0 35.7
complex
Plasmin-a2-antiplasmin
D-dimer
(50-500 μ§/1) 0 28.6
(<80 μg/l) - 32.7
Thrombin-antithrombin III complex D-dimer
Gl vs G2: p < 0.005 Gl vs G2: p < 0.05
Gl vs G3: n. s. Gl vs G3: ρ < 0.001
Gl vs G4: ρ < 0.001 Gl vs G4: n. s.
G2 vs G3: ρ < 0.001 G2 vs G3: ρ < 0.001
G2 vs G4: n. s. G2 vs G4: n. s.
G3 vs G4: ρ < 0.001 G3 vs G4: ρ < 0.001
0 41.6 0 29.4
50.0 - 11.8
Plasmin-<X2-antiplasmin
Gl vs G2: n. s.
Gl vs G3: n.s.
Gl vs G4: ρ < 0.001
G2 vs G3: ρ < 0.01
G2 vs G4: n. s.
G3 vs G4: ρ < 0.001
0 57.0
42.9
hypertrophy. The present study was not able to confirm
the results found by others. First, no coagulation path-
way activation and fibrin formation has ever been de-
scribed in prostatic carcinoma (12). Therefore, the coag-
ulation activation in prostatic carcinoma patients found
by others, may have a cause other than the prostatic
carcinoma. Second, the fibrinolysis marker D-dimer
showed significance in the present study and other
studies. However, the most direct fibrinolysis marker,
plasmin-a2-antiplasmin, did not. This may be due to the,
with other fibrin split products, cross-reacting D-dimer
test kits. Thus, fibrinolysis may not play such a promi-
nent role in prostatic carcinoma as described and ex-
pected. Before a definite answer can be given to this
matter, we think that new studies with larger patient
groups are necessary.
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